effects of three products containing Noscapine on COVID-19

Phase 2

Recruiting

Conditions: COVID-19
U07.1
COVID-19.

Registration Number: IRCT20180103038199N3

Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 160

Inclusion Criteria

Patients who are strongly suspected of having COVID 19 disease in terms of clinical findings and CT scan findings
Patients who are clinically classified and hospitalized as severe
Patients who have no organ damage.
Confirmation of RT-PCR test for SARS-CoV-2
Age under 80 years
confirmation of pneumonia by chest x-ray
Blood oxygen saturation below 93%
Relative stability of the cardiovascular status

Exclusion Criteria

Pregnant women
Lactating women
End stage patients

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Recovery time from the time of randomization of the studied patients to the improvement of clinical symptoms based on 7 common signs of improvement reported by the World Health Organization. Timepoint: before and 14 days after initiation of the intervention. Method of measurement: Relative criteria based on clinical symptoms as follows, 1: not hospitalized with resumption to normal activities, 2: not hospitalized but unable to resume normal activities, 3: hospitalized without the need for oxygen therapy, 4: hospitalized requiring supplemental oxygen, 5: hospitalized and need to receive high-speed oxygen from the nose or non-invasive ventilation or both, 6: hospitalized and need to receive oxygen using invasive ventilation or oxygen delivery from non-pulmonary routes or both, 7: death.;Hospital discharge. Timepoint: After initiation of the intervention. Method of measurement: Duration of hospitalization.

Secondary Outcome Measures